Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 14/20 | 0.69 |
| ▸ | ADCY8 | P40145 | 13/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597900 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17717055 | 0.81 | LMNA (0.67) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17716957 | 0.81 | ADCY1 (0.83) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17717090 | 0.79 | LMNA (0.66) | ADCY1ADCY8LMNAHTTTDP1 | |
| SCHEMBL17717122 | 0.79 | KDM4E (0.67) | ADCY1LMNAMAPTHTTTDP1 | |
| SCHEMBL17717032 | 0.79 | ADCY1 (0.69) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17716997 | 0.79 | ADCY1 (0.78) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17717063 | 0.77 | ADCY1 (0.87) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17716970 | 0.77 | ADCY1 (0.87) | ADCY1ADCY8LMNAMAPTHTT | |
| SCHEMBL17717038 | 0.77 | ADCY1 (0.87) | ADCY1ADCY8LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | disclosed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | ADCY1 2927/4885ADCY8 2449/4885LMNA 1893/4885 |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | ADCY1 2927/4885ADCY8 2449/4885LMNA 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.